文献速递白血病

癌症与白血病B组90203试验(Alliance):局限性高危前列腺癌根治性前列腺切除术联合或不联合新辅助化疗激素治疗

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2020-07-24

该研究将788例临床局限性高危前列腺癌患者随机分配至单纯根治性前列腺切除术组或新辅助化疗激素治疗(雄激素剥夺联合多西他赛75 mg/m2体表面积每3周1次共6周期)后根治性前列腺切除术组。主要终点3年生化无进展生存率两组无差异(0.89 vs 0.84,差值95%CI -0.01至0.11,P=0.11),新辅助化疗激素治疗组总生化无进展生存(HR 0.69,95%CI 0.48至0.99)、无转移生存(HR 0.70,95%CI 0.51至0.95)和总生存(HR 0.61,95%CI 0.40至0.94)改善。结论为主要终点未达到,数据不支持常规使用新辅助化疗激素治疗联合根治性前列腺切除术。

要点

  • 3年生化无进展生存率新辅助化疗激素治疗联合根治性前列腺切除术组0.89 vs 单纯根治性前列腺切除术组0.84,差异未达统计学显著(P=0.11)。
  • 新辅助化疗激素治疗组总生化无进展生存(HR 0.69,95%CI 0.48至0.99)、无转移生存(HR 0.70,95%CI 0.51至0.95)和总生存(HR 0.61,95%CI 0.40至0.94)优于单纯手术组。
  • 化疗期间3级和4级不良事件总体发生率分别为26%和19%。

核心结论

  • 主要研究终点3年生化无进展生存未达到;虽然次要终点有改善,但任何潜在获益必须与毒性权衡;数据不支持目前对临床局限性高危前列腺癌患者常规使用新辅助化疗激素治疗联合根治性前列腺切除术。

研究设计与样本

  • 随机对照试验,纳入788例临床局限性高危前列腺癌男性,随机分配至单纯根治性前列腺切除术组或新辅助化疗激素治疗(雄激素剥夺联合多西他赛75 mg/m2体表面积每3周1次共6周期)后根治性前列腺切除术组;主要终点为3年生化无进展生存。

主要发现

  • 中位随访时间6.1年;新辅助化疗激素治疗联合根治性前列腺切除术组与单纯根治性前列腺切除术组的3年生化无进展生存率分别为0.89和0.84(差值95%CI -0.01至0.11,P=0.11)。
  • 新辅助化疗激素治疗组相比单纯根治性前列腺切除术组:总生化无进展生存HR 0.69(95%CI 0.48至0.99),无转移生存HR 0.70(95%CI 0.51至0.95),总生存HR 0.61(95%CI 0.40至0.94)。
  • 化疗期间3级和4级不良事件总体发生率分别为26%和19%。

关键数值与推荐

  • 生化失败定义为血清前列腺特异性抗原水平>0.2 ng/mL且间隔至少3个月连续2次升高。
  • 新辅助化疗激素治疗方案:雄激素剥夺联合多西他赛75 mg/m2体表面积每3周1次共6周期。

临床怎么用

  • 原文结论指出数据不支持目前对临床局限性高危前列腺癌患者常规使用新辅助化疗激素治疗联合根治性前列腺切除术。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression-free survival (BPFS) over RP alone. PATIENTS AND METHODS: Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS: In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, -0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION: The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eastham JA, Heller G, Halabi S, et al. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020. PMID: 32706639. doi:10.1200/JCO.20.00315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。